|
|
Article: Alexion Pharmaceuticals Reports the Amelioration of Asthma Symptoms With Anti-C5 Therapy; - Preclinical studies presented at the World Allergy Organization Congress -.
- Article from:
- PR Newswire
- Article date:
- September 8, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Alexion Pharmaceuticals, Inc. is reporting today that anti-C5 monoclonal antibody therapy blocked the development of bronchial inflammation and reduced airway hyperresponsiveness in preclinical models of severe allergic asthma. The findings are reported today by Dr. Yi Wang, Senior Director of Preclinical Sciences at Alexion, in an oral presentation entitled, "Amelioration of asthma-like syndrome with a monoclonal antibody (mAb) specific for complement component C5," during the Asthma Therapy I session of the World Allergy Organization Congress, in Vancouver, British Columbia, Canada.
"A significant clinical need exists for the development of new, targeted ...